LigronBio

BREAKTHROUGH RESEARCH

Reversing Alzheimer’s via Gene Therapy and Molecular Glues

Founder & Nataraj

Alzheimer's Therapy : 9.2T / 2050

The Challenge

- Key Pathways (Amyloid Beta, Tau & Synaptic Loss) hard to Drug
- BBB Limits Drug Delivery
- Single Target Drugs Fail to Stop Progression

Why Current Therapies Fall Short



50M+
Current Cases

150M+
2050

50%
Genetic Inheritance / 2050

Too little = No Drug efficacy / Too much = Toxicity

Solution : Glu-NcAA TPD via Molecular Glues with Gene Therapy

How Molecular Glues Works: They Create A Bridge Between Disease-causing Proteins And The Cell's Natural Disposal Machinery (E3 Ligase), Triggering Protein Ubiquitination And Degradation Through The 26S Proteasome.



- Unlock Treatment for Undruggable Proteins
- Clearance Of Toxic Proteins
- Prevent Tau Protein Phosphorylation
- Prevent Neuroinflammation
- Restore Memory Function

Tau Degradation: A Breakthrough Pathway to Reverse Cognitive Decline

Reverses Neurodegeneration

DC_{50}: ≈ 57%



Reduced Aggregated Tau Intensity/Cell



Human Tau-K18-GFP HEK293

- ❑ Novel Tau-Targeted Therapeutic Platform
  - Selectively Degrades Pathological Tau Protein Aggregates
- ❑ Scalable Platform
  - Small-molecule, Manufacturable, and Cost-efficient
- ❑ De-risked Path
  - Clinically and Regulatorily Validated Modality
- ❑ Protected IP
  - Strong Patent Coverage Extending Through 2036

Degrading Toxic Aggregates, Restoring Neurons

Discovery Pipeline

Precision-Engineered Protein Degradation Targeting Multiple Neurodegenerative Pathways With Enhanced Selectivity Profiles

Glu-NcA Peptide-Tau Aggregate Degradation for AD Therapy

LIB-1226 c-RAF Protein Degradation For Treatment of AD

LIB-1306 Molecular Glue

TDP-43 Protein Degradation for Early-Onset of AD & ALS

LIB-067

Additional targeted protein degradation candidate in FTD

Discovery Programs

- Targeting 2028 For IND Filing

HumanAI™ & L-Tag Assay : Making the ‘Undruggable’ Druggable

(Provisional Patent Ap

AI- TrimatriX Analyzer ™

(Patent

Diagnostic Kit

(Patent Pending)

Therapeutics

Data Integration

Proteome Mapping

Validation in Live cells

Human clinical Trials

1 — 2 — 3 — 4 — 5 — 6 — Disease Therapy

Input

Amino acid/Peptide

Output

Molecular Glue discovery

Generati

Invitro & In Vivo Studies

Molecular Glue Optimization

AI-driven discovery

Rapidly identifies and optimizes molecular glues without requiring 3D protein structures

Membrane Penetration

Our compounds demonstrate excellent Membrane penetration and metabolic

GluNcAA Alzheimer's Treatment

GluNcAA Injection → Oral Molecular → Tau Aggregate Clearence → Maintenanc e Phase





mRNA-LNP Injection

Oral Pill

Reduced Neuronal Inflammation

Ongoing Therapy

One Injection / 6 Months

Daily or Twice Daily 3-7 days

Restoring Memory Loss

Injection & Oral Glue As Needed

Glues

One Injection every 4-6 weeks Drives Sustained Protein Clearance, Slowing Cognitive Decline And Restoring Memory

Once Or Twice Daily For 3–7 Days Following The Glu-NcAA Injection

Safe ty

Efficac y

Conveni ence

❑ Precision Targeting

- Right Protein, Right Time, Right Brain Exposure
- Eliminating Infusion Burden and Immune Side Effects

❑ Therapeutic Index

- >100× Vs. Traditional Inhibitors
- Prolonged Action : 24 - 48+ Hours Post-dose

❑ Precision Therapy

- One Pill. Right Dose. Right Target. Right Time.
- New Standard of Care

Safety + Superior Efficacy +

Market Share by 2035



64M / 2030

Revenue Projection

Revlimid Molecular Glue set as a

B2B Business Model

Upfront fees + Milestones + Royalties

Discovery Partnership Deals



Upfront fees + Milestones + Royalties

Asset Licensing Deals

Human AI - TriMatrix™ Analyzer™ Platform + Diagnostic Kit (L-Tag Assay)

- **Biomarker discovery and drug efficacy prediction**
- **Therapeutic Candidate Optimization**

Molecular Glue Therapeutic Candidates

Alzheimer's, ALS, Parkinsons & Oncology

Business & Clinical Development Strategy

Our strategic roadmap accelerates novel therapeutics from discovery through clinical trials, leveraging proprietary platforms to address critical unmet needs in neurodegenerative disease



Total Investment: $17.8M Over 36 Months Positions Lead Asset For Phase 1 Clinical Trials, With Potential For Accelerated Regulatory Pathways In Orphan Indications

We are Raising $3M Pre Seed (18Months) on a SAFE

Key Milestones Advancing Our Glu-NcAA Technology Through Proof-of-concept Validation

Q1

Glu-NcAA Tech & MC Development

35% Budget :
$1,05M

Q2

Medicinal Chemistry Optimization

16.7% Budget :
$500,000

Q3

Preclinical Validation Phase

13.3% Budget :
$400,000

Q4

InVivo Target Assessment & POC

18.3% Budget :
$550,000

R
Ol
20-50
X
Safe : 20% Discount

Investor Returns

- Equity Appreciation
- Licensing Deals
- Acquisition & Partnerships

$115K : Boot Strap
$100K : Angel Investor

Operational Costs Budget : $300,000 (10%) **IP Protection &**

Next-Gen Therapeutics

Computational Chemistry

Nataraj Pagadala, PhD

Co-Founder & CEO

Learning & Memory

Prof. Albert La

UC Irvine Center for the Neurobiology of Learning & Memory

Drug Metabolism & Pharmacokinetics

Prof. Oliver Boutaud

VANDERBILT UNIVERSITY

Animal Models

Christopher M. Butt, Ph.D.

VANDERBILT UNIVERSITY

Clinician

Dr. Venu

Pr

Immunology

Amir Landi, Ph.D.

Preclinical Discovery & Translational Research Leader

UNIVERSITY OF ALBERTA

Clinical Trials

Claudia Shojai, CPSM

Principal, Clinical Trial Operations

SponsorLink

Fractional CFO

Ashish Sinha

CEO @ StartupFin.co

Symeres

inotiv

Organix

CMTC

HitChem

WuXi Biologics

Regulatory

FDA-Regulated; Marketing Authorization Required Prior To Licensing

Streamlined Regulatory Strategy 351(a) BLA

$16.3 million over 3 to 4 years

POS = 70 to 75%*

~50–60% of FDA Approvals

Traditional Approval 505(b)1 NDA

$2.6 billion over 8 to 12 years

POS = 20%

LigronBio's Tau Degrader As A First-in-class Platform Therapy With Strong Regulatory Clarity And High Commercial Potential.

Health Crisis Than COVID-19

Molecular Glues

The New Revolution in Alzheimer’s Treatment



“We Are Fighting To Protect Future Generations From Alzheimer's”

LigronBio Inc.
Aquillius Innovation Hub,
10918 Technology Pl San Diego, CA 92127
Nataraj Pagadala, Ph.D. Founder & CEO
+1-858-366-3838
npagadala@ligronbio.com
https://www.ligronbio.com

Let’s